Establishment Labs (NASDAQ: ESTA - Get Free Report) and Pediatrix Medical Group (NYSE: MD - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends. Profitability This table compares Establishment Labs and

MD's Q4 EPS miss estimates as revenues dip, but same-unit gains and a stronger 2026 EBITDA outlook signal mixed momentum.

Pediatrix Medical Group, Inc. (MD) Q4 2025 Earnings Call Transcript

It missed the consensus analyst net income estimate in its final quarter of 2025. It did beat on revenue, however.

Pediatrix Medical Group (MD) came out with quarterly earnings of $0.5 per share, missing the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.51 per share a year ago.

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Reports Fourth Quarter Results.

Pediatrix Medical Group (NYSE: MD - Get Free Report) is expected to issue its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect the company to announce earnings of $0.53 per share and revenue of $486.23 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q4 2025 earning

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group 2025 Fourth Quarter Conference Call/Webcast Scheduled for Thursday, February 19, 2026.

New York State Common Retirement Fund boosted its holdings in shares of Pediatrix Medical Group, Inc. (NYSE: MD) by 87.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,950 shares of the company's stock after purchasing an additional 54,705 shares

Pediatrix Medical Group, Inc. (NYSE: MD - Get Free Report) has been assigned a consensus rating of "Hold" from the six brokerages that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12-month target price among analysts